unknown
Stage
About
Abologix is a biopharmaceutical company developing monoclonal antibodies targeting Junction Adhesion Molecule C (JAM-C) and Olfactomedin-like protein 3 (Olfml3) for cancer therapies, particularly focusing on oncological indications.
Explore Abologix's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.